The American corporation of Gastro...

The American corporation of Gastroenterology's Practice Parameters Committee has issued updated practice guidelines for the treatment of ulcerative colitis in adults. The guidelines were generated through an expert panel's review of published evidence and outline the preferr approaches to the treatment of patients with ulcerative colitis, a chronic disease characterized according to diffuse mucosal inflammation of the colon and marked by the agency of bloody diarrhea, rectal urgency, and tenesmus. Ulcerative colitis affects 250000 to 500000 family in the United States each year resulting in imbrue hospital and drug costs as well as missed work. The full text of the updated practice guidelines, which originally appeared in the July 2004 issue of the American Journal of Gastroenterology, is available at http://www.acg.gi.org/physicians/guidelines/UlcerativeColitisUpdate.pdf.

The quality of evidence onward which a recommendation is based is as follows:

Grade A: Homogenous evidence from multiple well-designed randomized (therapeutic) or cohort (descriptive) controll trials, each involving a number of participants to be of sufficient statistical power.

Grade B: Evidence from at least individual large well-designed clinical trial with or without randomization, from cohort or case-control analytic studies, or well-designed meta analyses.

Grade C: Evidence based forward clinical experience, descriptive studies, or reports of apt committees.

Diagnosis and Management

In patients with persistently sanguinary diarrhea, rectal urgency, or tenesmus, stool examinations, sigmoidoscopy, and biopsy should be performed to confirm the port of colitis and to omit the presence of infectious etiologies. When obtaining the patient's history, the clinician should inquire about factors known to exacerbate symptoms of ulcerative colitis, like as recent or past smoking cessation or use of nonsteroidal anti-inflammatory drugs

Because infectious agents can bring into view symptoms indistinguishable from ulcerative colitis, microbiologic analyses for bacteria, parasites, and amoebas should be performed. In particular, infection with Escherichia coli O157:H7 and Clostridium difficile (in patients who have been freshly hospitalized or who have received antibiotics) should be excluded

Proctosigmoidoscopy or colonoscopy will reveal the mucosal changes characteristic of ulcerative colitis: los of the typical vascular pattern, granularity, friability, and ulceration. These changes usually appear in the distant rectum and proce proximally to involve part or all of the colon although isolated cecal inflammation may be seen

If a diagnosis of Crohn's disease is being considered, radiographs of the small bowel will help distinguish it from ulcerative colitis. The diagnosis may be Crohn's disease if histology finds noncaseating granulomas or microscopic focality. In patients with acute attack of bloody diarrhea, mucosal biopsy may help distinguish ulcerative colitis from infectious colitis. In patients who have ulcerative colitis, the following occur: the mucosa more commonly demonstrates separation, distortion, and atrophy of crypts; inflammatory small rooms in the lamina propria; neutrophils in the vault epithelium; elevated plasma cells near the vault bases; and basilar lymphoid aggregates.

Management

Treatment for ulcerative colitis asks to improve quality of life on inducing and maintaining remission of symptoms and inflammation. The reach of the proximal margin of inflammation, assessed by dint of endoscopy, is either distal (limited to below the splenic rate of incurvation and within reach of topical therapy) or extensive (extending proximal to the splenic curvature requiring systemic medication). Because an important criterion for treatment of ulcerative colitis is quality of life, patients' quality-of-life relate tos should be elicited, particularly as they relate to function in gymnasium at work, or in personal relationships. Management should be tailored to suited these concerns.

Clinical and endoscopic findings will allow the clinician to assess the disorder's severity, which is characterized as mild (fewer than four stools daily, with or without progeny no systemic signs of toxicity, normal erythrocyte sedimentation rate [ESR]); moderate (more than four stools daily, minimal signs of toxicity); relentless (more than six bloody stools daily, evidence of toxicity [fever tachycardia, anemia, elevated ESR]); or fulminant (more than 10 stools daily, continuous bleeding, toxicity, abdominal tendernes and distension, descendants transfusion requirement, colonic dilation onward abdominal plain films).

Patients with mild or moderate distal colitis may be treated with: oral aminosalicylate (ASA) (4 to 6 g by means of day of sulfasalazine in four divided doses; 2 to 48 g by day of mesalamine in three divided doses [Evidence A]; 675 g by day of balsalazide in three divided doses); topical mesalamine (suppositories, 500 mg twice a day, or enemas, in doses of 1 to 4 g); or topical steroids (100-mg hydrocortisone enema or 10 percent hydrocortisone foam). The combination of oral and topical ASAs is more effective than either alone (oral mesalamine, 24 g by day and 4 g for day mesalamine enema) (Evidence A). If patients do not rejoin to mesalamine enemas or suppositories, oral prednisone (up to 40 to 60 mg through day) should be administered.